Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Neurobiol Aging. 2023 May 26;129:178–184. doi: 10.1016/j.neurobiolaging.2023.05.013

Table 1.

Participants’ baseline characteristics

Men (N=214) Women (N=261) Sex difference
Mean (SD) or N (%) as noted Range Mean (SD) or N (%) Range p-value
Demographics
Age, years 75.2 (8) 60–94 73.9 (8.2) 60–98 0.086
Race and ethnicity, n (%)
 Chinese 2 (0.9) - 4 (1.5) - -
 Black 34 (16) - 78 (30) - -
 Filipino 0 (0) - 3 (1.2) - -
 Japanese 0 (0) - 2 (0.8) - -
 Other Asian or Other Pacific Islander 3 (1.4) - 6 (2.3) - -
 Other Non-White 4 (1.9) - 0 (0) - -
 White 171 (80) - 167 (64) - -
 Not Classifiable 0 (0) - 1 (0.4) - -
Education, years 18.3 (3.1) 7–32 17.3 (2.7) 12–24 <0.001
Waist circumference, cm 95.7 (9.7) 73–146.5 83.1 (11.1) 56.4–111.2 <0.001
Brain Aging measures
SPARE-BA score, unitless 73.6 (10.8) 46.2–99.7 72.6 (9.9) 48.4–97.9 0.697
SPARE-BA Slope (annual rate of change) 1.3 (1.1) −2.3–5.7 1.1 (0.9) −2–4.6 0.052
Number of brain MRI visits per participant 3.4 (1.5) 2–10 3.5 (1.4) 2–11 0.787
Follow-up, years 4.7 (2.4) 1–11 4.8 (2.3) 1–10 0.512
Other measures of interest
Apolipoprotein E ε4 carrier status, n (%) 44 (21) (n=207) - 67 (26) - 0.276
Subsequent cognitive impairment/dementia 36 (17%) - 24 (9%) - 0.017
Total cholesterol, mg/dL 171 (32) 88–255 193 (35) 102–373 <0.001
High-density lipoprotein, mg/dL 55 (14) 23 – 100 69 (16) 34 – 128 <0.001
Low-density lipoprotein, mg/dL 96 (29) 23 – 182 106 (31) 38 – 276 <0.001
Triglycerides, mg/dL 100 (54) 33 – 497 92 (40) 34 – 357 0.075
Medication use for high cholesterol, n (%) 90 (42) - 101 (39) - 0.510
Estradiol, ng/dL 2.5 (0.8) (n=204) 0.5–5.3 0.7 (0.6) (n=230) 0.1 – 4.4 <0.001
Total testosterone, ng/dL 489.1 (185.0) (n=204) 11.0–1192.0 22.8 (13.6) (n=239) 3.4–97.0 <0.001
Bioavailable testosterone, ng/dL 112 (46) (n=203) 8.8–310 3.7 (2.8) (n=224) 0.7 – 18 <0.001
Sex hormone-binding glycoprotein, nmol/L 58.4 (24.4) (n=203) 14.0–139.4 74.9 (38.4) (n=241) 13.3–334.7 <0.001
Lipid variables
Acylcarnitines: Beta-oxidation rate 0.13 (1.00) −2.71 – 2.77 −0.10 (0.99) −3.48 – 2.99 0.013
Acylcarnitines: Long-chain 0.11 (0.98) −3.76 – 2.11 −0.09 (1.01) −3.76 – 1.92 0.050
Acylcarnitines: Medium-chain 0.06 (0.88) −2.79 – 2.30 −0.05 (1.09) −2.79 – 2.18 0.327
Acylcarnitines: Short-chain 0.12 (0.94) −2.86 – 2.77 −0.10 (1.04) −4.03 – 3.01 0.023
Ceramides: Very Long-chain −0.26 (1.01) −2.96 – 2.34 0.21 (0.94) −2.44 – 2.96 <0.001
Ceramides: Long-chain −0.31 (1.00) −2.98 – 2.23 0.26 (0.93) −2.72 – 2.66 <0.001
Glycoceremides: Very Long-chain −0.23 (1.02) −2.84 – 2.20 0.19 (0.94) −2.40 – 2.88 <0.001
Glycoceremides: Long-chain −0.28 (1.05) −3.31 – 2.50 0.23 (0.89) −2.21 – 3.17 <0.001
Glycerolipids & Cholesteryl Esters:Very Long-chain −0.31 (1.01) −3.24 – 2.27 0.25 (0.92) −1.90 – 2.49 <0.001
Glycerolipids & Cholesteryl Esters:Long-chain −0.27 (0.96) −3.26 – 1.81 0.22 (0.98) −3.18 – 2.79 <0.001
Sphingomyelins: Very Long-chain −0.40 (0.99) −3.24 – 2.35 0.33 (0.89) −1.86 – 2.90 <0.001
Sphingomyelins: Long-chain −0.51 (0.92) −3.05 – 2.11 0.42 (0.86) −2.51 – 3.70 <0.001
Triglycerides: Very Long-chain −0.01 (1.07) −4.15 – 2.86 0.01 (0.94) −3.60 – 2.62 0.890
Triglycerides: Long-chain 0.01 (1.07) −2.88 – 3.16 −0.01 (0.95) −2.84 – 2.82 0.763

Note: p-values were based on t-tests for continuous variables and chi-square tests for categorical variables. Sex differences in SPARE-BA index and lipid variables were adjusted for age. Lipid variables were based on log-transformed values and standardized to Z scores. The bold number indicates significance at a two-tailed p<0.05.